Quantification of Celiac Disease Gluten Epitopes
Scientists have published a novel method to detect multiple celiac disease-epitopes in wheat extracts simultaneously using liquid chromatography–multiple reaction monitoring mass spectrometry (LC–MRM–MS).
Scientists have published a novel method in the Journal of Chromatography A to detect multiple celiac disease-epitopes in wheat extracts simultaneously using liquid chromatography–multiple reaction monitoring mass spectrometry (LC–MRM–MS).1
Celiac disease is caused by an immune response in the small intestine from eating gluten proteins. An enzyme-linked immunosorbent assay (ELISA) is the standard testing method for food, but this can be inaccurate and does not differentiate between gluten proteins. Lead author Hetty van den Broeck told The Column: “This newly developed method based on mass spectrometry quantifies specifically celiac disease stimulating epitopes. This is not possible by ELISA, which detects gluten proteins in general by using a monoclonal antibody. Mass spectrometry allows specific detection and quantification of multiple CD-epitopes at the same time. This is necessary because of the complex genome of bread wheat and the many different CD-epitopes to which CD-patients can respond differentially.”
In the current study, gluten extracts were prepared from wheat and extracted prior to LC–MRM–MS analysis. The authors developed the method to detect peptides known to induce the strongest immune response, as well as peptides with amino acid substitutions that make them harmless. The method was able to quantify different peptide isoforms, showing that a modern wheat variety, Toronto, contained the highest level of CD immunogenic peptides.
The team are continuing their work to test and select reduced immunogenic wheat varieties, van den Broeck told The Column. She said: “We are also working on the development of screening body fluids from CD-patients for the presence of these epitopes or other specific peptide biomarkers for CD.”- B.D.
Reference
1. H.C. van den Broeck et al., J. Chromatogr. A1391, 60–71 (2015).
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
